Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

LANTHEUS HOLDINGS, INC.

(LNTH)
  Report
Delayed Nasdaq  -  04:00 2022-09-30 pm EDT
70.33 USD   +1.91%
09/13Lantheus, GE Healthcare Say Study Shows 18F flurpiridaz PET Radiotracer Can Improve Coronary Artery Disease Detection
MT
09/13GE Healthcare and Lantheus Phase III Clinical Trial Finds [18F]flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease
GL
09/13GE Healthcare and Lantheus Phase III Clinical Trial Finds flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

SVB Securities Raises Lantheus Holdings Price Target to $110 From $100, Maintains Outperform Rating

08/05/2022 | 10:50am EDT


© MT Newswires 2022
All news about LANTHEUS HOLDINGS, INC.
09/13Lantheus, GE Healthcare Say Study Shows 18F flurpiridaz PET Radiotracer Can Improve Cor..
MT
09/13GE Healthcare and Lantheus Phase III Clinical Trial Finds [18F]flurpiridaz PET Radiotra..
GL
09/13GE Healthcare and Lantheus Phase III Clinical Trial Finds flurpiridaz PET Radiotracer C..
AQ
09/13GE Healthcare and Lantheus Holdings Inc Announces Phase III Clinical Trial Finds [¹8F]f..
CI
09/13GE, Lantheus Say Heart Disease Tracer Trial Met Key Endpoints
DJ
09/08Insider Sell: Lantheus Holdings
MT
09/08Insider Sell: Lantheus Holdings
MT
09/01Lantheus to Present at the Wells Fargo Healthcare Conference
GL
08/25Lantheus Holdings Shares Rise After B. Riley Resumes Coverage
MT
08/25B. Riley Securities Resumes Lantheus Holdings at Buy with $102 PT, Views as 'Best Posit..
MT
More news
Analyst Recommendations on LANTHEUS HOLDINGS, INC.
More recommendations
Financials (USD)
Sales 2022 899 M - -
Net income 2022 187 M - -
Net Debt 2022 - - -
P/E ratio 2022 29,2x
Yield 2022 -
Capitalization 4 835 M 4 835 M -
Capi. / Sales 2022 5,38x
Capi. / Sales 2023 4,80x
Nbr of Employees 612
Free-Float 97,6%
Chart LANTHEUS HOLDINGS, INC.
Duration : Period :
Lantheus Holdings, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LANTHEUS HOLDINGS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 70,33 $
Average target price 103,20 $
Spread / Average Target 46,7%
EPS Revisions
Managers and Directors
Mary Anne Heino Chief Commercial Officer
Robert J. Marshall Chief Financial Officer & Treasurer
Brian A. Markison Director
Simon Robinson Senior VP-Research & Pharmaceutical Development
Bela S. Denes Vice President-Medical Affairs
Sector and Competitors